- life sciences/pharma sector
-
3rd Annual Antibody Discovery and Development Forum
Analyse the use of antibodies in novel therapeutic areas and apply within successful business models in an evolved regulatory environment
Event Date: 17-18 Jun 2010
Location: Radisson Blu Hotel, Amsterdam, Netherlands
- key conference speakers
-
Prof. Jan van De Winkel President of Research and Development and Chief Scientific Officer, Genmab Dr. Bridget Heelan Clinical Assessor, Medicines and Healthcare products Regulatory Agency (MHRA) Dr. William Strohl Vice President, Biologics, Johnson & Johnson Prof. Alois Lang Director of Development and Professor of Immunology, GeNeuro Dr. Robert Friesen Vice President, Antibody Discovery, Crucell
- key conference topics
-
- Genmab on achieving accelerated FDA approval of CD20-targeting mAb Arzerra
- GeNeuro outlining the technology involved in the treatment of
- ESBATech AG reviewing the generation of single change
- EpiVax Inc developing Tregitope technology
- TRION Pharma providing insight into the next generation of antibodies in treating cancer
- conference focus
-
The antibody therapy field is continuously expanding and this conference will provide the opportunity to hear from leading ind The antibody therapy field is continuously expanding but facing challenges when developing efficacious antibody drugs in novel therapeutic areas such as CNS diseases and viral infections. The issues involved are drug target identification, limiting hypersensitivity reactions and the development of adequate platform technology to produce fit-for-purpose antibodies in a cost effective and efficient manner. The path to the clinic continues with further challenges such as achieving FDA approval and sustaining your drug’s market survival against biosimilar competition.
This 3rd annual marcus evans conference will provide valuable knowledge to enhance drug efficacy with the latest innovations in technology with solutions for improving antibody selection and engineering. You will be advised on overcoming regulatory pressures on issues such as immunogenicity assessment and biosimilars with insight from key experts to make your product unique. This in turn will link to harnessing this therapeutic potential successfully through business models and achieving the best return on investments.